Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Manufacturing & supply

OXB acknowledges role as Aura's manufacturer for ocular cancer drug bel-sar

The UK contract manufacturer says it will make Aura Biosciences' virus-like drug conjugate for late-stage trials, with a possible route into commercial supply, though terms remain undisclosed.

17 Nov 2026 · OXB · Company news

OXB, the UK contract development and manufacturing organisation focused on cell and gene therapies, said on 17 November 2026 that it has a supply and manufacturing relationship with Aura Biosciences. The company will help produce belzupacap sarotalocan, known as bel-sar, Aura's virus-like drug conjugate for cancers of the eye.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Manufacturing & supplyAll →